US Trends

will medicare cover zepbound in 2026

Medicare is not expected to cover Zepbound broadly for weight loss in 2026, but many plans may cover it for obstructive sleep apnea (OSA) in people who meet specific criteria.

Key 2026 takeaway

  • Current law still blocks Medicare from covering drugs used only for weight loss, including Zepbound, so there is no broad 2026 Medicare coverage for weight loss alone.
  • Medicare Part D and Medicare Advantage (Part C) plans can cover Zepbound when it is prescribed for moderate to severe obstructive sleep apnea in adults with obesity, if the drug is on that plan’s formulary.

When Zepbound may be covered

If you are on Medicare, Zepbound coverage in 2026 generally requires:

  • A documented diagnosis of moderate to severe obstructive sleep apnea.
  • Body mass index (BMI) of 27 or higher and participation in reduced‑calorie diet and increased physical activity, as part of the treatment plan.
  • Enrollment in:
    • A Part D drug plan that lists Zepbound on its formulary, or
    • A Medicare Advantage (Part C) plan that includes drug coverage and lists Zepbound.

Medicare does not cover Zepbound solely for obesity or weight management, even though it has FDA approval for weight loss.

What happened with “2026 expansion”?

  • CMS previously floated the idea of reinterpreting the long‑standing exclusion on weight‑loss drugs and exploring broader coverage starting in 2026, which created a lot of online buzz and forum speculation.
  • Later reporting indicates the government ultimately did not move forward with a broad anti‑obesity drug expansion for 2026, so the core rule (no pure weight‑loss coverage) remains in place.

Real‑world 2026 experiences (forum chatter)

Online Zepbound communities report that:

  • Some people on Medicare see Zepbound listed only for OSA and not for weight loss on their 2026 Part D formularies.
  • Others note that if Zepbound is not on the formulary, it will not count toward the new out‑of‑pocket cap (around the low‑$2,000 range) for Part D in 2026, making the drug effectively full price unless an exception is granted.

These posts also highlight that plan rules vary by region and insurer, so two Medicare users can have very different experiences in 2026.

How to check your 2026 coverage

To get a clear answer for your situation:

  1. Check your Part D or Medicare Advantage formulary
    • Look up “Zepbound (tirzepatide)” and see whether it’s covered and under which conditions (OSA vs weight loss).
  1. Review prior authorization criteria
    • Many plans require proof of OSA severity, BMI, and lifestyle changes before approving Zepbound.
  1. Ask your prescriber to code for OSA if appropriate
    • If you truly have qualifying obstructive sleep apnea, accurate diagnosis and documentation can be critical for coverage.
  1. Call your plan or a licensed Medicare broker
    • Medicare insurance brokers typically do not charge you and can help compare 2026 plans that might include Zepbound for OSA.

Bottom line: For 2026, Medicare may cover Zepbound only when prescribed for obstructive sleep apnea (with obesity and other criteria met) and when your specific Part D or Medicare Advantage plan includes it on the formulary; it is not covered broadly for weight loss alone.

Information gathered from public forums or data available on the internet and portrayed here.